Table 2 Treatments received by participants within the ‘On Treatment’ group
Last line of treatment | HL | Aggressive B-NHL | Indolent B-NHL | PTCL |
|---|---|---|---|---|
Chemotherapy | 27 | 0 | 0 | 1 |
Anti-CD20 alone | 0 | 2 | 27 | 0 |
Anti-CD20 + chemotherapy | 0 | 36 | 14 | 0 |
Anti-CD20 + chemotherapy-free agent | 0 | 1 | 6 | 0 |
Bendamustine | 1 | 2 | 0 | 0 |
Bendamustine + anti-CD20 | 0 | 0 | 5 | 0 |
BTK inhibitors | 0 | 0 | 17 | 0 |
Venetoclax | 0 | 0 | 7 | 0 |
BTK inhibitor + venetoclax | 0 | 0 | 2 | 0 |
CAR-T-cell therapy | 0 | 0 | 0 | 0 |
Autologous stem cell transplant | 0 | 4 | 2 | 0 |
Allogeneic stem cell transplant | 0 | 0 | 0 | 0 |
Others | BV (2), BV + bendamustine (1) | CPI (1) Bispecific Ab (1) | Bispecific Ab + lenalidomide (1) | PI3K inhibitor (1) BV (1) Ciclosporin (1) |
